Skip to content

Calculus portfolio companies contributing to the fight against COVID-19

While the global pandemic continues to affect our everyday lives, it is important to adapt quickly to a fast changing environment. Several of our portfolio companies have rapidly pivoted to play their part in the fight against COVID-19, and we would like to highlight their efforts below. Mologic A medical diagnostics firm Omega Diagnostics has CE-Marked … Continued

Scancell to initiate development of novel DNA vaccine against COVID-19

Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, announces that it has initiated a research programme to develop a vaccine for COVID-19. The project will be led by Professor Lindy Durrant, Chief Scientific Officer and Professor of Cancer Immunotherapy at the University of Nottingham, in collaboration with scientists in the … Continued

Mologic launches new lab-based COVID-19 antibody tests

Follows successful validation by Liverpool School of Tropical Medicine and St George’s, University of London With manufacturing support from Omega Diagnostics, the laboratory-based test aims to deliver up to 46,000 results per day Health services and key worker communities in the UK and Africa will be prioritised for access Bedfordshire, UK, 20 APRIL 2020: Mologic Ltd, a … Continued

Oxford BioTherapeutics Announces Second Oncology Drug Candidate Selected to Advance

Oxford BioTherapeutics (“OBT”) a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, announced that Boehringer Ingelheim (“BI”) has selected a second asset to advance into formal IND enabling studies. The asset discovery was enabled by OBT’s proprietary OGAP® target discovery platform. It is one of several assets that have … Continued